ReviewCell & bioscience2025
Domain acquisition enabled functional expansion of the TFIIS transcription factor family.
Review in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
TFIIS and its homologs were long considered a delimited family of transcription factors, for the ability to induce RNA Polymerase II backtracking and nascent RNA cleavage. Recent studies however show that the relevant domains, which correspond to the TFIIS middle and carboxyterminal regions, are used to control transcription by additional protein architectures. The TFIIS middle region is paired with a SPOC domain in BYE1, the founder protein of the subfamily, and in its homologs; this combination of domains accommodates additional features such as a small zinc finger resembling the TFIIS carboxyterminal region. In metazoans, the architecture has evolved additional extensions to act on downstream RNA processing. Here, we argue in favor of a single protein superfamily encompassing TFIIS, BYE1, and their metazoan homologs. We conclude that the TFIIS middle domain comprises a common Pol2-interacting domain, shared by various generic protein functions. Domain composition of the vertebrate BYE1 homologs indicates a role in transcription elongation. Depending on the combination with other structures, the TFIIS middle domain may promote mutually exclusive activities, for example backtracking versus RNA synthesis and splicing. In this way, exchange of TFIIS for other superfamily members supports the separate Pol2 actions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.